Engagement of the GABA to KCC2 Signaling Pathway Contributes to the Analgesic Effects of A3AR Agonists in Neuropathic Pain

Amanda Ford, Annie Castonguay, Martin Cottet, Ashley M. Symons-Liguori, Timothy Doyle, Terrance M. Egan, Todd W. Vanderah, Yves De Koninck, Kenneth A. Jacobson, and Daniela Salvemini

1Department of Pharmacological and Physiological Science, St. Louis University School of Medicine, St. Louis, Missouri 63104, 2Institut Universitaire en Santé Mentale de Québec, Québec City, Quebec G1J 2G3, Canada, 3Department of Psychiatry & Neuroscience, Université Laval, Québec City, Quebec G1K 7P4, Canada, 4Department of Surgery, Center for Anatomical Science and Education, St. Louis University School of Medicine, St. Louis, Missouri 63104, 5Department of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona 85724-5050, and 6Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0810

Introduction

Chronic pain represents an enormous socioeconomic public health problem that severely limits quality of life for its sufferers. Unfortunately, current treatment strategies are either ineffective (Dworkin et al., 2007) or are accompanied by unacceptable side effects (McNicol et al., 2003).

Adenosine, an endogenous purine nucleoside whose actions are mediated through the activation of four G-protein-coupled adenosine receptor (AR) subtypes (A1, A2A, A2B, and A3), has been hypothesized to play an inhibitory role in nociceptive pathways. Indeed, adenosine and selective AR agonists have potent antinociceptive effects in neuropathic pain of various etiologies (Sawynok, 2007). However, the clinical use of A1/A2AR agonists is limited by serious cardiovascular side effects (Zylka, 2011). We recently demonstrated that A3AR agonists have potent analgesic actions in several models of chronic neuropathic pain (Chen et al., 2012; Janes et al., 2014, 2015). Interestingly, selective, orally bioavailable A3AR agonists, such as 1-deoxy-1-[6-[[3-iodophenyl]methyl]amino]-9H-purin-9-yl]-N-methyl-β-D-ribofuranuronamid (IB-MECA), are in Phase II/III clinical trials for non-pain-related indications and exhibit acceptable safety profiles (Fishman et al., 2012).

Although evidence supports the use of A3AR agonists in the management of chronic pain, the underlying mechanism(s) of action are unknown. A3ARs are expressed throughout the nervous system in relevant pain areas (i.e., the rostral ventromedial...
medulla and the dorsal horn of the spinal cord) and found in neurons and glial cells (Borea et al., 2015; Little et al., 2015). We have characterized the central effects of A3AR, finding that A3AR activation inhibits nociception by engaging bulbospinal analgesic pathways and suppressing the responses of spinal wide dynamic range projection neurons during persistent pain states (Little et al., 2015). Despite the potent inhibitory actions of A3AR on neurotransmission, A3AR analgesia is not mediated by opioid or endocannabinoid pathways (Chen et al., 2012; Little et al., 2015). We therefore questioned whether A3AR agonists might exert their inhibitory actions on nociception by engaging the GABA inhibitory system.

In neuropathic pain states, tonic GABA inhibition is suppressed in superficial dorsal horn nociceptive neurons and enhanced excitatory signaling is no longer regulated by inhibitory controls, leading to a net neuronal hyperexcitability (Zeilhofer et al., 2012). Loss of GABA inhibition can result from a number of pathophysiologic changes in key components throughout the GABA system. In pathophysiologic pain states, reduced levels of spinal GABA (Stiller et al., 1996; Eaton et al., 1998) and its synthesizing enzyme, GAD65 (Eaton et al., 1998; Moore et al., 2002) are observed, whereas the functional expression of the GABA transporter GAT-1, which removes GABA from the synapse (Daemen et al., 2008; Liu et al., 2013), is increased. Additionally, there is a reduction in the activity and expression of the K,Cl cotransporter, KCC2 (Coulll et al., 2003; Price et al., 2005), which maintains the anion gradient necessary for the inhibitory actions of the GABA A receptor (GABA A R) in neurons. This impairment of GABA signaling produces behavioral hypersensitivity resembling that observed after peripheral nerve injury (Enna and McCarson, 2006). While therapies that enhance GABAergic signaling produce significant analgesia (Malan et al., 2002; McCarson and Enna, 2014), the use of pro-GABAergic therapies as analgesics remains limited by adverse CNS side effects.

Taken together, we hypothesize that A3AR agonists reverse neuropathic pain by modulating key components that regulate chloride-mediated inhibition at the spinal level.

Materials and Methods

Experimental animals. Male Sprague Dawley rats (200–220 g starting weight) or male CD1 mice (20–30 g) from Harlan Laboratories were housed 2–4 per cage (for rats) and 5 per cage (for mice) in a controlled environment (12 h light/dark cycle) with food and water available ad libitum. All experiments were performed in accordance with the International Association for the Study of Pain and the National Institutes of Health guidelines on laboratory animal welfare and the recommendations by St. Louis University Institutional Animal Care and Use Committee. All experiments were conducted with the experimenters blinded to treatment conditions.

Chronic constriction injury (CCI) model. CCI to the sciatic nerve of the left hind leg in mice and rats was performed under general anesthesia using the well-characterized Bennett model (Bennett and Xie, 1988). Briefly, animals were anesthetized with 3% isoflurane/O2 inhalation and maintained on 2% isoflurane/O2 for the duration of the surgery. The left thigh was shaved, scrubbed with Nolvasan, and a small incision (1–1.5 cm in length) was made in the middle of the lateral aspect of the left thigh to expose the sciatic nerve. The nerve was loosely ligated around the entire diameter of the nerve at three distinct sites (spaced 1 mm apart) using silk sutures (6.0, mice; 4.0, rats). The surgical site was closed with a single muscle suture and a skin clip. Pilot studies established that under our experimental conditions peak mecano-allodynia develops by D7–D10 following CCI. Test substances or their vehicles were given intraperitoneally (i.p.) at peak mecano-allodynia.

Test compounds. IB-MECA was purchased from Tocris Bioscience. MRS1523 (3-propyl-6-ethyl-5-[(ethylthio]carbonyl]-2-phenyl-4-propyl-3-pyridine-carboxylate), bicuculline ([R-(R*,S*)]-6-(5,6,7,8-tetrahydro-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl) furyl][3,4-e]-1, 3-benzodioxol-6-(6H)-one), and VU0240531 (N-(4-methyl-2-thiazolyl)-2-[6-(phenyl-3-pyridazinyl)thio]-acetamide) were obtained from Sigma-Aldrich. MRS5698 (15R,2R,35,4>R,5>S)-4-(6-(3-chlorobenzylamino)-2-(3,4-difluorophenyl) ethynyl)-9H-purin-9-y1)-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide) was synthesized as previously described (Tosh et al., 2012).

Behavioral testing. Mechano-allodynia was measured after animals were allowed to acclimate to elevated cages with a wire mesh floor for 15 min. The plantar aspect of the hindpaw was probed with calibrated von Frey filaments (Stoelting; mice: 0.07–2.00 g; rats: 0.407–26 g) according to the “up-and-down” method (Dixon, 1980) (see Fig. 2). Behavioral testing was done before surgery on D0, on D7 after surgery (peak development of mecano-allodynia), and at different time points (30 min to 5 h) after drug/vehicle administration (given on D7). Animals were then killed by asphyxiation with CO2 and subsequently decapitated as a secondary method, and tissues were collected for further examination.

Electrophysiology. Cultured HEK293 cells were transfected with equal amounts (1 μg) of cDNA encoding the α1, β2, and γ2 subunits of the rat GABA A receptor and eGFP (0.3 μg) using Effectene (QiAGEN). Agonist-induced changes in membrane current were recorded using the amphoterin perforated-patch technique as previously described (Samways et al., 2011). Drugs were applied using the Perfusion Fast-Step SF-77 System (Warner Instruments).

Immunoblotting. Dorsal horn tissues were obtained from the lower lumbar enlargement (L4-L6) region of the spinal cord and stored immediately at –80°C. Relative protein expression was assessed as previously described (Doyle et al., 2011). Briefly, frozen tissues were homogenized in lysis buffer (20 μl Tris-Cl, pH 7.4, 150 μl NaCl, 0.1% CHAPS, 0.5% Triton X-100, 0.1% SDS, 2 μg EGTA, 5% glycerol, 50 μM sodium fluoride, 1 μM sodium orthovanadate, 1 μM sodium molybdate, 0.1 μM PMSF, 1x phosphatase inhibitor mixture (Sigma-Aldrich), and 1x protease inhibitor mixture (Sigma-Aldrich).), sonicated, and clarified by centrifugation. Total protein concentration was determined by BCA, and samples were heat denatured in 2x Laemmli buffer supplemented with β-mercaptoethanol and then stored at –20°C until assayed. Proteins were resolved by Tris-glycine-SDS electrophoresis with a 4%–20% gel and transferred to nitrocellulose membrane (Bio-Rad). After blocking with 5% nonfat milk or 5% BSA in PBS-T, the membranes were probed overnight at 4°C with primary antibody. Bands were visualized with secondary HRP conjugated antibodies (Cell Signaling Technology, 1:2500). Immunoblot images were captured and analyzed using ChemiDoc MP and Image Lab 5.0 (Bio-Rad). All data are expressed as the percentage densitometric signal from the ipsilateral lysate over the animal-matched contralateral lysate normalized to respective β-actin loading control.

Immunoprecipitation. Total serine phosphorylated protein fractions were immunoprecipitated from ipsilateral and contralateral spinal cord lysates (25 μg). Briefly, agarse-conjugated mouse monoclonal anti-phosphoserine beads (Sigma) were equilibrated in immunoprecipitation buffer (20 μl Tris-Cl, pH 7.4, 150 μl NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol) supplemented with 1 μl PMSF, 50 mM NaF, 1 mM Na2VO4, 1 mM NaN3MoO4, and 1x phosphatase and protease inhibitor mixtures (Sigma). The equilibrated beads (25 μl) were added to each total protein lysate (25 μg) and brought to 500 μl with immunoprecipitation buffer. After incubation for 18 h at 4°C with continuous inversion, the lysates/bead mixtures were centrifuged 5 min at 1000 × g at 4°C and the supernatant was collected for β-actin (Sigma, 1:2000) analysis of protein loading. The beads were washed 3 times with ice-cold 1× PBS with centrifugation for 5 min at 1000 × g at 4°C then heat-denatured in 2x Laemmli buffer (25 μl) supplemented with β-mercaptoethanol for 5 min at 95°C. The denatured supernatant was subjected to SDS-PAGE (4%–20% TGX, Bio-Rad) and immunoblotting to nitrocellulose. The serine phosphorylation of KCC2, GAT1, and GAD65 was identified by increased immunoreactivity. The antibodies used were as previously described (KCC2: Millipore, 1:1000; GAT1: Abcam, 1:1000; GAD65 (Cell Signaling Technology, 1:1000), and secondary HRP conjugated anti-rabbit IgG antibodies (Cell Signaling Technology, 1:2500). Immunoblot images were captured and
analyzed using ChemiDoc MP and Image Lab 5.0 (Bio-Rad). All data are expressed as the percentage densitometric signal from the ipsilateral lysate over the animal-matched contralateral lysate normalized to respective β-actin loading control.

**Immunofluorescence.** After behavioral measurements, lumbar spinal cords were harvested from rats, placed into cryomolds containing optimal cutting temperature embedding compound (Electron Microscopy Sciences), rapidly frozen in an isopropanol/dry ice bath, and stored at −80°C. Transverse sections (20 μm) were cut in a cryostat, collected on gelatin-coated glass microscope slides, and stored at −20°C. Spinal cord sections were fixed in 10% buffered neutral formalin (10 min), rinsed in PBS, blocked for 1 h (10% normal goat serum, 2% BSA, 0.2% Triton X-100 in PBS), and then immunolabeled as previously described (Little et al., 2012) using a primary antibody, rabbit IgG polyclonal anti-KCC2 phosphorylated serine 940 (pKCC2; 1:100, incubated 18 h at 4°C, Rockland), followed by several PBS rinses and incubation (2 h room temperature in the dark) with a goat-anti-rabbit IgG antibody conjugated to AlexaFluor-568 (1:250, Invitrogen). After a series of PBS rinses, coverslips were mounted with Fluorogel II containing DAPI (Electron Microscopy Sciences) and photographed with an Olympus FX1000 MPE confocal microscope (multiline argon lasers with excitation at 405 and 543 nm) using a 10× objective (UPLSAPO; 0.4 NA) for regional fluorescence intensity image analysis and a 20× objective (UPLSAPO; 0.75 NA) and 60× oil-immersion objective (PLAPON; 1.42 NA) with 2.4× optical zoom (0.1 μm pixel dimensions in the x-y plane and the pinhole set at 1 Airy unit) for higher-magnification images. Images were acquired within the dynamic range of the microscope (i.e., no pixel intensity values of 0 or 255 in an 8-bit image). Sections omitting primary antibody or treated with rabbit IgG at equivalent concentrations to primary antibodies were used as controls yielding only nonspecific background fluorescence. The fluorescence intensity of immunolabeled pKCC2 was calculated as previously described (Chey et al., 2000) using a primary antibody, rabbit IgG polyclonal anti-KCC2 phosphorylated serine 940 (pKCC2; 1:100, incubated 18 h at 4°C, Rockland), followed by several PBS rinses and incubation (2 h room temperature in the dark) with a goat-anti-rabbit IgG antibody conjugated to AlexaFluor-568 (1:250, Invitrogen). After a series of PBS rinses, coverslips were mounted with Fluorogel II containing DAPI (Electron Microscopy Sciences) and photographed with an Olympus FX1000 MPE confocal microscope (multiline argon lasers with excitation at 405 and 543 nm) using a 10× objective (UPLSAPO; 0.4 NA) for regional fluorescence intensity image analysis and a 20× objective (UPLSAPO; 0.75 NA) and 60× oil-immersion objective (PLAPON; 1.42 NA) with 2.4× optical zoom (0.1 μm pixel dimensions in the x-y plane and the pinhole set at 1 Airy unit) for higher-magnification images. Images were acquired within the dynamic range of the microscope (i.e., no pixel intensity values of 0 or 255 in an 8-bit image). Sections omitting primary antibody or treated with rabbit IgG at equivalent concentrations to primary antibodies were used as controls yielding only nonspecific background fluorescence. The fluorescence intensity of immunolabeled pKCC2 was calculated as previously reported (Little et al., 2012) in the superficial dorsal horn (laminae I and II) of the lumbar spinal cord. The mean fluorescence intensity (MFI) was calculated by Equation 1 as follows:

\[ \text{MFI} = i(pp^2 + p^2) \]  

where \( i \) is the mean gray value, \( pp \) is the positive pixel area, and \( p \) is total pixel area. Image analysis was performed using the NIH freeware program ImageJ (version 1.43) (Rasband, 1997–2011). Images received background threshold corrections before analysis using the automated ImageJ intermodes histogram-based threshold function. The superficial dorsal horn was outlined on images at the L4, L5, and L6 levels bilaterally using the ImageJ ROI tool. The borders of this region were determined and confirmed using cresyl violet-stained sections of regions adjacent to immunolabeled sections and an atlas (Paxinos and Watson, 1998). Relative MFI was calculated as fold change normalized to the fluorescence intensity of the contralateral (unaffected) dorsal horn (i.e., dividing the fluorescence intensity from superficial dorsal horn of the ipsilateral side with the change in extracellular \( \text{Cl}^- \) transport. Lifetime images were acquired every 10 s for a period of 7 min. After a control period of 50 s, perfusion solution was switched to ACSF containing 15 mM KCl (osmolarity adjusted using mannitol) to reverse KCC2-mediated \( \text{Cl}^- \) transport (Chorin et al., 2011). Lifetime measurements were compiled over time after the switch in extracellular \( [\text{K}^-]_t \) to quantify the rate of \( \text{Cl}^- \) import in cells through KCC2. Lifetime values for each cell were averaged over the whole-cell body area and extracted for each time point using custom MATLAB software. Briefly (Digman et al., 2008), we converted the photon timing histograms of each acquired lifetime image to phasor plots. Then, for every time-point, ROIs corresponding to cell bodies were selected and added to a new phasor. Lifetime times of all cells bodies were averaged for each slice at each time point to generate the lifetime time course. All transport rates were tested with the same starting \( [\text{Cl}^-]_t \) (i.e., in the period when there is no \( \text{Cl}^- \) load prior to the change in extracellular \( K^- \)).

**ED50 calculations.** The ED50 for the A3AR agonists, IB-MECA and MRS5698, to reverse mecano-allodynia from CCI was determined by a three-parameter, nonlinear regression analysis of normalized paw withdrawal threshold (PWT) data using the following equation:

\[ \%\text{Reversal} = \frac{(\text{PWT}_{1h} - \text{PWT}_{D0})}{(\text{PWT}_{D0} - \text{PWT}_{D7})} \times 100 \]

where \( \text{PWT}_{1h} = \text{PWT} \) (g) at 1 h after agonist injection on D7, \( \text{PWT}_{D7} \) = \( \text{PWT} \) (g) on D7 before agonist, and \( \text{PWT}_{D0} = \text{PWT} \) (g) on D0 before surgery. Nonlinear regression analysis was performed using GraphPad Prism version 5.04 (GraphPad Software).

**Statistical analysis of data.** Data are expressed as mean ± SEM for n animals. Time-dependent behavior was analyzed by two-tailed, two-way repeated-measures ANOVA with Bonferroni post hoc comparisons to D7 behaviors. Data for Cl− transport were analyzed by one-way ANOVA followed by Bonferroni post hoc comparisons. Protein expression data were determined by Welch’s corrected, unpaired, one-tailed Student’s t test. Significant differences were defined as a value of \( p < 0.05 \). All statistical analysis was performed using SPSS (Release 21.0, IBM).

**Results**

A3AR agonists reverse CCI-induced mecano-allodynia via a spinal site of action

To examine a potential site of action for the anti-allodynic effects of A3AR agonists, mice were pretreated intrathecally with the selective A3AR antagonist MRS1523 (Li et al., 1998) prior to the systemic administration of IB-MECA. As previously demonstrated (Chen et al., 2012), systemic IB-MECA (1.0 mg/kg; i.p.; \( n = 6 \) ) given on D7 significantly reverses established mecano-allodynia in the CCI model with peak reversal occurring at 1 h. Local blockade of spinal A3AR with MRS1523 (3 nmol; \( n = 6 \)), given by intrathecal (i.th.) injection completely blocked IB-MECA’s anti-allodynic effects (Fig. 1A; repeated-measures ANOVA, \( F_{(2,4)} = 75.4, p = 0.001 \)), whereas MRS1523 alone had no effect.

To confirm that IB-MECA exerts antinoceptive at the level of the spinal cord, we examined the antinociceptive properties of IB-MECA when administered spinally. As expected, intrathecal administration of IB-MECA (3, 10, 30, or 60 nmol; i.th.; \( n = 6 \)), but not its vehicle, dose-dependently reversed CCI-induced mecano-allodynia with a peak reversal at 1 h and an ED50 of 7.73 nmol (95% CI: 5.2–11.5; Fig. 1B; Greenhouse–Geisser corrected repeated-measures ANOVA, \( e = 0.474, F_{(4,24)} = 12.1, p = 0.001 \)).

To extend our previous work and strengthen evidence of a role for A3AR agonism in pain relief, we used the agent MRS5698, which represents a chemical class unique from IB-MECA. MRS5698 is both orally bioavailable and >1000-fold more selective for A3AR over other AR subtypes; as such, MRS5698 is an
excellent pharmacological tool for investigating the mechanism(s) of A3AR analgesia (Tosh et al., 2012). As with IB-MECA, systemic MRS5698 dose-dependently reverses CCI-induced mechano-allodynia (Little et al., 2015). Spinal MRS5698 (3, 10, 30, 60 nmol; i.th.; n = 6) dose-dependently reversed mechano-allodynia with a calculated ED50 of 6.2 nmol (95% CI: 4.1–9.4; Fig. 2B; Greenhouse–Geisser corrected repeated-measures ANOVA, F(6, 24) = 15.9, p < 0.001). Moreover, inhibiting spinal A3AR signaling with intrathecal MRS1523 (3 nmol; i.th.; n = 6) blocked the anti-allodynic effects of systemic MRS5698 (1.0 mg/kg; i.p.; n = 6), confirming an A3AR mechanism of action at the spinal level (Fig. 2A; repeated-measures ANOVA, F(2, 4) = 90.2, p < 0.001). We extended our findings to another rodent model of CCI: as in the mouse model, spinal MRS5698 (60 nmol; i.th.; n = 6) reversed CCI-induced mechano-allodynia in rats (Fig. 2C; Greenhouse–Geisser corrected repeated-measures ANOVA, ϵ = 0.242, F(6, 6) = 5.9, p = 0.019), whereas the vehicle had no effect.

Bicuculline blocks the anti-allodynic actions of MRS5698
To assess whether the spinal mechanism(s) of action of A3AR agonists might involve GABAergic signaling, we first tested whether the anti-allodynic actions of MRS5698 are dependent on spinal GABAA receptor activation. Spinal pretreatment with the selective GABAA antagonist, bicuculline (0.5 mg/kg; i.th.; n = 6), 15 min before systemic MRS5698 (1.0 mg/kg; i.p.; n = 6) abolished the ability of MRS5698 to reverse CCI-induced mechano-allodynia. This effect was observed in both mouse (Fig. 3A; Greenhouse–Geisser corrected repeated-measures ANOVA, ϵ = 0.297, F(6, 12) = 8.8, p = 0.001) and rat models of CCI (Fig. 3B; Greenhouse–Geisser corrected repeated-measures ANOVA, ϵ = 0.275, F(6, 12) = 8.4, p = 0.001) with the dose chosen from previ-
Cristovâo-Ferreira et al., 2011

MRS5698 restores the function of proteins involved in the regulation of GABA bioavailability

In experimental neuropathic pain, extracellular GABA is depleted through the downregulation of the GABA-synthesizing enzyme GAD65 and the upregulation of the GABA transporter GAT-1; these biological changes are associated with a reduction in the amount of GABA available to bind to GABA receptors and ion channels (in ~50 assays). This screening was provided by the National Institute of Mental Health Psychoactive Drug Screening Program. MRS5698 was tested at a concentration of 10 μM and did not show significant binding to GABAA receptors (Paolletta et al., 2014). The inability of MRS5698 to act as a GABAA receptor agonist was confirmed electrophysiologically using the perforated-patch technique. GABA (1 μM) evoked robust and reproducible inward currents in voltage-clamped HEK293 cells transiently expressing either rat α1β2 (n = 5) or α1β2γ2L (n = 5) GABA receptors. By contrast, MRS5698 (10 μM) had no effect (Fig. 5C,D).

MRS5698 restores the function of proteins involved in the regulation of GABA bioavailability

In experimental neuropathic pain, extracellular GABA is depleted through the downregulation of the GABA-synthesizing enzyme GAD65 and the upregulation of the GABA transporter GAT-1; these biological changes are associated with a reduction in the amount of GABA available to bind to GABA receptors and related pain behaviors. The observed inactivation of GAD65 and activation of GAT-1 are caused by dephosphorylation of their regulatory serine residues (Wei et al., 2004; Cristovâo-Ferreira et al., 2009). We therefore asked whether the development of CCI-induced neuropathic pain is associated with GAD65 and GAT-1 modification and whether those modifications are reversed with MRS5698 treatment. Because previous evidence suggests that changes in both spinal GAD65 and GAT-1 occur ipsilateral to nerve injury (Moore et al., 2002), serine phosphorylation of these proteins was analyzed in dorsal horn tissues ipsilateral to nerve injury and harvested from animals at 1 h after MRS5698 or vehicle administration (peak analgesia) with contralateral tissues within the same animal used as a control. We found that CCI (n = 10) decreased the serine phosphorylation of GAD65 (Fig. 4A) and GAT-1 (Fig. 4B) in immunoprecipitate from ipsilateral dorsal horn as compared to the contralateral side. MRS5698 (1.0 mg/kg; i.p.; n = 10) treatment reversed CCI-induced serine dephosphorylation of GAD65 (Fig. 4A; Welch’s corrected one-tailed two-sample t(14.1) = −2.2, p = 0.021) and GAT-1 (Fig. 4B; Welch’s corrected one-tailed two-sample t(12.7) = −2.3, p = 0.021) consistent with the reestablishment of GABA bioavailability. We observed no changes in total expression levels in either GAD65 (Welch’s corrected one-tailed two-sample t(17.9) = 1.3, p = 0.109) or GAT-1 (Welch’s corrected one-tailed two-sample t(15) = 0.90, p = 0.190).

VU0240551 blocks the anti-allodynic actions of MRS5698

To assess the ability of A2AR agonists to modulate spinal KCC2, we tested whether spinal KCC2 activity is necessary for MRS5698-mediated reversal of mecha-no-allodynia. Pretreatment with the selective KCC2 inhibitor, VU0240551 (0.27 μg; i.th.; n = 6), abolished the anti-allodynic effects of systemic MRS5698 (1.0 mg/kg; i.p.; n = 6). This effect was observed in both the mouse (Fig. 5A; repeated-measures ANOVA, F(6,12) = 25.9, p = 0.001) and rat (Fig. 5B; Greenhouse–Geisser corrected repeated-measures ANOVA, e = 0.478, F(6,12) = 37, p = 0.001) models of CCI with the dose chosen from previous studies (Delpire et al., 2009; Austin and Delpire, 2011). At the dose tested, VU0240551 did not affect PWT in naive animals (data not shown).

MRS5698 restores KCC2 function in CCI animals

Spinal dorsal horn tissues were collected from CCI rats receiving MRS5698 or vehicle treatment at peak analgesia (1 h after administration) and assayed for phosphoserine and total KCC2 protein expression levels. Similar to GAD65 and GAT-1, previous reports indicated that changes in KCC2 activity and expression only occur ipsilateral to the nerve injury. We found that serine phosphorylation of KCC2 in the ipsilateral dorsal horn was decreased in response to CCI (n = 10). MRS5698 administration (1.0 mg/kg; i.p.; n = 10) restored serine phosphorylation of KCC2 on the ipsilateral side (Fig. 5C; Welch’s corrected one-tailed two-sample t(17.7) = −2.053, p = 0.028). Total KCC2 was not changed in either group (Fig. 5C; Welch’s corrected one-tailed two-sample t(16.3) = 0.067, p = 0.474). Phosphorylation of the serine 940 residue on KCC2 is the only site explicitly shown to increase KCC2 activity. Thus, we confirmed that phosphorylation at ser-
ine 940 was increased in the ipsilateral spinal cord in CCI animals receiving MRS5698. Indeed, systemic MRS5698 (1.0 mg/kg, i.p.), but not vehicle enhanced pKCC2, in the ipsilateral laminae I and II of the spinal dorsal horn as compared to the contralateral side (Fig. 6; Welch’s corrected one-tailed two-sample \(t\)-test, \(p < 0.05\) versus Veh, Welch’s corrected one-tailed unpaired Student’s \(t\)-test).

To assess whether KCC2 serine phosphorylation is associated with changes in KCC2 activity, we assayed the ability of nerve injury to produce a decrease in KCC2-mediated Cl\(^-\) transport; furthermore, we asked whether MRS5698 restores normal function of KCC2 in mature neurons. We measured the effect of MRS5698 on Cl\(^-\) transport in lamina II of spinal cord slices obtained from rats with CCI and control slices from naive or sham animals. KCC2 function was assessed by measuring K\(^+\)-driven Cl\(^-\) influx via fluorescence lifetime measurements of the Cl\(^-\)-sensitive probe MQAE. Changing the [K\(^+\)]\(_e\), from 2.5 to 15 mM caused inversion of KCC2 transport and subsequent Cl\(^-\) accumulation inside cells. The rate of intracellular Cl\(^-\) change was measured as an index of KCC2-mediated transport rate. CCI animals displayed a slower rate of Cl\(^-\) transport as compared to sham animals (0.069 and 0.117 ns/min, respectively). When treated with MRS5698 (1 mg/kg; \(n = 6\); i.p.), the Cl\(^-\) transport activity was restored to values obtained from naive rats (0.109 ns/min in naive animals and 0.109 ns/min in CCI animals treated with MRS5698; Fig. 7A–C; one-way ANOVA, \(F(3) = 4.2, p = 0.013\)).

**Discussion**

Chronic neuropathic pain represents a major public health problem that will only intensify as an aging population suffers from...
pain-associated diseases such as arthritis, cancer, and diabetes. Currently, the most effective treatments are either NSAIDs or opiates, which are only moderately effective and exhibit adverse side effects that lead to discontinuation of use (McNicol et al., 2003; Dworkin et al., 2007). Novel mechanism-based treatments for chronic pain are severely lacking and represent a massive unmet clinical need.

Adenosine receptor agonists show potent antinociceptive effects in pain models of various etiologies (Zylka, 2011). However, adenosine-related therapies have been restricted to local delivery as they exhibit dangerous cardiovascular side effects when administered systemically. Recently, we have shown that specific A3 AR agonists have potent analgesic actions in models of chronic neuropathic pain (Chen et al., 2012; Janes et al., 2014, 2015; Little et al., 2015). Given that A3 AR agonists such as IB-MECA are already in Phase II/III clinical trials for psoriasis, hepatitis, rheumatoid arthritis, dry eye, and glaucoma and are exhibiting acceptable safety profiles (Fishman et al., 2012), they show clinical prospective as a novel therapeutic approach to pain.

To examine possible mechanisms underlying the antinociceptive actions of A3 AR agonists, it is important to first understand their pharmacological characteristics and potential sites of action. Here, we confirm and extend our recent finding that A3 AR activation in CNS areas related to pain processing is critical to A3 AR agonist-mediated antinociception (Little et al., 2015). We show that IB-MECA exerts its actions at least in part via a spinal mechanism, as
blocking spinal A3AR activation with MRS1523 precludes the anti-allodynic effects of systemically administered IB-MECA. We corroborate our findings using the chemically distinct and more selective A3AR agonist MRS5698. Intrathecal administration of MRS5698 dose-dependently reverses mechano-allodynia and spinally administered MRS1523 blocks the antinociception produced by systemically administered MRS5698. Furthermore, we validate our previous findings in a rat CCI model, demonstrating that the proposed A3AR mechanism is not species-specific and permitting future biochemical analyses that require larger amounts of tissue from a small, specific region of the spinal cord.

The GABAergic signaling pathway plays an integral role in coordinating both the perception of and response to painful stimuli within the CNS; accordingly, GABA dysfunction is implicated in a number of pain states (Enna and McCarson, 2006). Extensive research efforts have been aimed at the development of drugs that enhance GABAergic signaling and have led to the targeting of not only GABA receptors, but also GABA-associated transporters and enzymes (Jasmin et al., 2004) such as GAT-1 (Schousboe et al., 2004) and GAD65 (Jain, 2008; Vit et al., 2009). Consequently, GABA receptor agonists as well as inhibitors of GABA uptake and metabolism display potent antinociceptive properties in a range of preclinical pain models (Enna and McCarson, 2006). Unfortunately, it has proven difficult to exploit GABA-specific strategies as the activation of GABA receptors in non-nociceptive areas of the CNS yields unfavorable side effects. We offer that A3AR agonists may represent a unique opportunity to tap into the beneficial actions of the GABA signaling pathway while avoiding undesirable side effects in the treatment of chronic pain.

In the present work, we demonstrate that the spinal mechanism of MRS5698 antinociception involves GABA signaling as a
GABA_A antagonist prevents the anti-allodynic action of A3AR agonists. We did not examine the involvement of the GABA_B receptor subtype as GABA_AR mechanisms are more readily investigated and understood in pathological pain states. We show that CCI produces a relative loss of phosphorylation of GAD65, an enzyme responsible for GABA synthesis, and GAT-1, a GABA reuptake transporter, whereas MRS5698 treatment maintains the phosphorylation status of GAD65 and GAT-1. Serine phosphorylation is known to activate GAD65 and stabilize it within the plasma membrane (Wei et al., 2004) and serine phosphorylation of GAT-1 signals for internalization and inactivation of the transporter (Law et al., 2000; Whitworth and Quick, 2001) such that the net effect of MRS5698 treatment is likely to increase synaptic GABA availability. Restriction of the effect of MRS5698 to the ipsilateral (injured) side supports our previous finding that A3AR plays a prominent role in modulating pathophysiological pain without altering normal protective pain sensation (Chen et al., 2012; Little et al., 2015).

Following peripheral nerve injury, pharmacological enhancements in extracellular GABA can persist beyond the time frame of analgesic efficacy (Cui et al., 1997), suggesting that increases in GABA availability alone fail to compensate for an underlying dysfunction of GABA_ARs in pathological pain. Extensive evidence suggests that this dysfunction is due to the downregulation and decreased activity of KCC2, a postsynaptically restricted cotransporter that functions to maintain the chloride gradient and is crucial to GABA-mediated postsynaptic inhibition (Williams et al., 1999; Kahle et al., 2008; Miletic and Miletic, 2008; Janssen et al., 2011). In the present work, we highlight the protective effect of MRS5698 administration on KCC2 function: we demonstrate that the anti-allodynic actions of MRS5698 require KCC2 activity as the selective KCC2 inhibitor, VU0240551, completely abrogates the beneficial effects of MRS5698. Additionally, administration of MRS5698 enhances the serine phosphorylation of KCC2 at Ser940, which is to date the only site phosphorylated of KCC2 (Williams et al., 1999; Kahle et al., 2008; Miletic and Miletic, 2008; Janssen et al., 2011). Indeed, we demonstrate that the rate of KCC2-dependent Cl^- extrusion is decreased in CCI versus sham animal spinal cord slices, and MRS5698 administration attenuates this loss of Cl^- transport rate. These data indicate that an A3AR-mediated restoration of KCC2-dependent Cl^- transport in CNS neurons may underlie the ability of MRS5698 to restore GABAergic neurotransmission in neuropathic pain.

To date, it is unknown how A3AR modifies the phosphorylation status of GAD65, GAT-1, and KCC2 to promote GABA function. One possible mechanism is through the A3AR-mediated activation of protein kinase C (PKC): CNS A3ARs can produce PKC activation in neurons by coupling to the G_α protein through signaling pathways (Abbraccchio et al., 1995; Dunwiddie et al., 1997). Previous studies have shown that GAD65 is phosphorylated almost exclusively by PKCε (Wei et al., 2004) and it has been demonstrated that adenosine can activate this PKC isoform in the instance of adenosine-mediated neuroprotection (DiCapua et al., 2003). Furthermore, PKC is responsible for phosphorylating KCC2 on serine, threonine, and tyrosine residues as a mechanism of regulating intrinsic ion transport rate, cell surface stability, and plasmalemmal trafficking (Kahle et al., 2013). Phosphorylation of KCC2 at Ser940 is specifically PKC-dependent (Lee et al., 2007), suggesting that an A3AR-to-PKC mechanism could feasibly underlie MRS5698-mediated enhancements in GABAergic signaling.

Alternatively, PKC-dependent phosphorylation of spinal KCC2 can be mediated by the serotonin (5-HT) axis: activation of 5-HT_3A produces PKC activation of KCC2 in spinal neurons and subsequently strengthened neuronal inhibition (Bos et al., 2013). Although the effect of serotonin in pain can be bidirectional, sufficient evidence implicates activation of 5-HT receptor subtypes in descending nociceptive inhibition: projections from the rostral ventromedial medulla elicit the release of serotonin in the spinal dorsal horn and this action can lead to antinociception (Wei et al., 2010; Hossaini et al., 2012; Ossipov et al., 2014). We have demonstrated the role of A3AR in descending inhibitory mechanisms (Little et al., 2015); accordingly, the modulation of descending serotonergic projections by MRS5698 could lead to the observed effects on the GABA-to-KCC2 pathway.

In contrast, the effects of MRS5698 could be mediated on a broader scale by the neuroinhibitory effects of adenosine on glutamatergic signaling. There is evidence that KCC2 is regulated in an activity-dependent fashion in neurons (Puskarjov et al., 2012) and that this mechanism is relevant in neuropathic pain (Zhou et al., 2012). Indeed, excitatory NMDAR activity can lead to the dephosphorylation of KCC2 at Ser940 (Lee et al., 2011). Because adenosine signaling functions as a vital “fine-tuning” mechanism for neurotransmission in the CNS (Wall and Richardson, 2015) and plays the role of a negative neuromodulator in excitatory synapses (Zhang et al., 2015), A3AR activation may prevent the activity-dependent dephosphorylation of KCC2 and subsequent dysfunction in GABA signaling.

Lastly, it is important to consider that MRS5698 could elicit changes in GABAergic signaling by abrogating glial-driven mechanisms of GABA dysfunction in neuropathic pain. To this end, glial-derived BDNF signaling is known to play a pronociceptive role in rodent CCI (Chen et al., 2014) by downregulating KCC2 and disrupting Cl^- homeostasis, thereby reducing the strength of GABA_A and glycine receptor-mediated postsynaptic inhibition (Biggs et al., 2010; Ferrini and De Konincx, 2013). In this paper, we have not examined whether the A3AR impinges upon the BDNF/TrkB/KCC2 pathway and we are not excluding a potential effect of A3AR agonists on this pathway. It is unlikely that MRS5698 acts directly on TrkB as an off-target because the observations in our manuscript are not consistent with the effects of a TrkB agonist: in our studies, we have identified Ser940 on KCC2 (Lee et al., 2007) as a critical site of A3AR-mediated regulation. In contrast, TrkB has only been documented to modify Tyr515 on KCC2 in the CNS (Rivera et al., 2004; Choe et al., 2015), and this phosphorylation event produces transporter internalization rather than an increase in transporter activity. Additionally, TrkB activity is not known to regulate the phosphorylation of GAD65 or GAT-1; it has been suggested that TrkB influences these enzymes through a CREB-dependent mechanism of transcriptional regulation (Sanchez-Huertas and Rico, 2011). On the other hand, it is conceivable that MRS5698 may impact BDNF/TrkB/KCC2 signaling by inhibiting the release of BDNF from glial cells as a parallel mechanism to the phosphorylation events we observe in A3AR-mediated restoration of GABAergic function. We have previously demonstrated the capacity of A3AR activation to attenuate astrocyte reactivity and neuroinflammatory response in chemotherapy-induced peripheral neuropathy (Janes et al., 2015) and additionally, A3AR activation may provide neuroprotection by inhibiting the reactive chemotaxis of microglia (Choi et al., 2011). As such, it is possible that an A3AR-mediated reduction in glial activation could preclude glial BDNF release and relieve TrkB-mediated alterations in GABA signaling in contribution to the restoration of GABA signaling that we have observed.
Collectively, the findings presented herein provide a pharmacological rationale for the development of A3AR agonists as a novel approach to the treatment of chronic pain. The present work supports our hypothesis that A3AR agonists attenuate neuropathic pain through modulation of the GABAergic signaling pathway. These data provide not only important mechanistic data about the action of A3AR agonists, but also demonstrate the advantage of A3AR as a two-pronged approach to restoring GABAergic function in chronic pain: enhancing GABA bioavailability within the synaptic cleft while also enhancing its efficacy by potentiating KCC2 activity (summarized in Fig. 8). A3AR agonists represent a unique opportunity to tap into the potent beneficial actions of two important inhibitory pain pathways (adenosine and GABA) while avoiding the adverse effects observed with modulatory drugs targeted to these pathways to date.

References
Janssen SP, Truin M, van Kleef M, Joosten EA (2011) Differential GABAe-